Shujun Yang

Efficacy and safety of regorafenib as second-line treatment for patients with hepatocellular carcinoma and macrovascular invasion and(or) extrahepatic metastasis

Yan Zhao, Weiling Liu, Lu Zheng, 2023, Journal of gastrointestinal oncology.

KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial

Yuanyuan Zhao, Jingxun Wu, Gang Chen, 2024, Cell reports. Medicine.

First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study.

Y. Bai, Jufeng Wang, Shegan Gao, 2024, Nature medicine.